Results 1 to 10 of about 9,994 (144)

Implementation of the plasma MYCN/NAGK ratio to detect MYCN amplification in patients with neuroblastoma [PDF]

Molecular Oncology, 2020
Detection of amplification of the MYCN gene is essential for determining optimal treatment and estimating prognosis of patients with neuroblastoma (NB).
Qian Zhao, Yan Su, Wang Bo
exaly   +6 more sources

MYCN amplification defines an aggressive phenotype in IDH‐mutant gliomas [PDF]

Journal of Pathology: Clinical Research
In alignment with the latest WHO classification system, which underscores the integration of molecular alterations in glioma diagnosis and grading, this study investigates the prognostic significance of MYCN amplification in IDH‐mutant gliomas, a ...
Fang Wang, Shaoyan Xi
exaly   +3 more sources

Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification [PDF]

Cancer Communications, 2019
Background Interphase fluorescence in situ hybridization (FISH) of bone marrow cells has been confirmed to be a direct and valid method to assess the v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN) amplification in ...
Qian Zhao, Zhixia Yue, Chao Gao
exaly   +4 more sources

MYCN amplification plus 1p36 loss of heterozygosity predicts ultra high risk in bone marrow metastatic neuroblastoma [PDF]

Cancer Medicine, 2022
Background This study aimed to better understand the prognostic effect of multiple genetic markers and identify more subpopulations at ultra high risk of poor outcome in bone marrow (BM) metastatic neuroblastoma (NB).
Zhi‐Xia Yue, Tian‐Yu Xing, Wen Zhao, Qian Zhao, Xi‐Si Wang, Yan Su, Chao Gao, Shu‐Guang Liu, Xiao‐Li Ma   +8 more
doaj   +2 more sources

Lipid Metabolic Reprogramming in Embryonal Neoplasms with MYCN Amplification. [PDF]

Cancers (Basel), 2023
Tumor cells reprogram their metabolism, including glucose, glutamine, nucleotide, lipid, and amino acids to meet their enhanced energy demands, redox balance, and requirement of biosynthetic substrates for uncontrolled cell proliferation. Altered lipid metabolism in cancer provides lipids for rapid membrane biogenesis, generates the energy required for
Talapatra J, Reddy MM.
europepmc   +3 more sources

MYCN amplification and ATRX mutations are incompatible in neuroblastoma. [PDF]

Nat Commun, 2020
Abstract Aggressive cancers often have activating mutations in growth-controlling oncogenes and inactivating mutations in tumor-suppressor genes. In neuroblastoma, amplification of the MYCN oncogene and inactivation of the ATRX tumor ...
Zeineldin M, Federico S, Chen X, Fan Y, Xu B, Stewart E, Zhou X, Jeon J, Griffiths L, Nguyen R, Norrie J, Easton J, Mulder H, Yergeau D, Liu Y, Wu J, Van Ryn C, Naranjo A, Hogarty MD, Kamiński MM, Valentine M, Pruett-Miller SM, Pappo A, Zhang J, Clay MR, Bahrami A, Vogel P, Lee S, Shelat A, Sarthy JF, Meers MP, George RE, Mardis ER, Wilson RK, Henikoff S, Downing JR, Dyer MA.   +36 more
europepmc   +7 more sources

Therapeutic potential of targeting MYCN: A case series report of neuroblastoma with MYCN amplification. [PDF]

Medicine (Baltimore), 2020
Neuroblastoma (NB) with MYCN amplification has a poor prognosis and high mortality. The potential molecular biological relationship between clinical features and MYCN amplification should be explored.NB patients were examined by fluorescence in situ hybridization (FISH) for MYCN amplification in the tumor mass or bone marrow samples to determine ...
Huang C, Jiang S, Yang J, Liao X, Li Y, Li S.   +5 more
europepmc   +3 more sources

Definition of parameters and thresholds to detect MYCN amplification in retinoblastomas. [PDF]

Virchows Arch
Retinoblastoma is a malignant childhood neoplasm where MYCN amplification defines a subset of tumors with worse prognosis. FISH (fluorescence in situ hybridization) represents a fast and reliable method to measure gene copy numbers in various tumors but has not yet been systematically evaluated in retinoblastoma.
Bielefeld C, Hugo T, Sievers N, Ketteler P, Biewald E, Kiefer T, Papaioannou K, Tüller P, Ryl T, Busch M, Rawitzer J, Schildhaus HU, Ting S.   +12 more
europepmc   +3 more sources

Predicting MYCN amplification in paediatric neuroblastoma: development and validation of a 18F-FDG PET/CT-based radiomics signature [PDF]

Insights into Imaging, 2023
Objectives To develop and validate an 18F-FDG PET/CT-based clinical-radiological-radiomics nomogram and evaluate its value in the diagnosis of MYCN amplification (MNA) in paediatric neuroblastoma (NB) patients.
Luo-Dan Qian, Shu-Xin Zhang, Si-Qi Li, Li-Juan Feng, Zi-Ang Zhou, Jun Liu, Ming-Yu Zhang, Ji-Gang Yang   +7 more
doaj   +2 more sources

MYCN amplification drives an aggressive form of spinal ependymoma. [PDF]

Acta Neuropathol, 2019
Spinal ependymal tumors form a histologically and molecularly heterogeneous group of tumors with generally good prognosis. However, their treatment can be challenging if infiltration of the spinal cord or dissemination throughout the central nervous system (CNS) occurs and, in these cases, clinical outcome remains poor.
Ghasemi DR, Sill M, Okonechnikov K, Korshunov A, Yip S, Schutz PW, Scheie D, Kruse A, Harter PN, Kastelan M, Wagner M, Hartmann C, Benzel J, Maass KK, Khasraw M, Sträter R, Thomas C, Paulus W, Kratz CP, Witt H, Kawauchi D, Herold-Mende C, Sahm F, Brandner S, Kool M, Jones DTW, von Deimling A, Pfister SM, Reuss DE, Pajtler KW.   +29 more
europepmc   +7 more sources